Oral Prostanoids and PAH

Goals and Learning Objectives

Program Overview

Oral Compounds That Target the Prostacyclin Pathway

Pathophysiologic Pathways Targeted by PAH Therapies

FDA Approved PAH Therapies

Risk Stratification of Patients ESC/ERS Guidelines

High-Risk Patients Not Candidates for Oral Prostanoids

Treatment Goal To Achieve Low-Risk Status

Treatment Algorithm ESC/ERS Guidelines

Intermediate-Risk Patients Potential Candidates for Oral Prostanoids

Example of a Potential Candidate for Oral Prostanoid

FREEDOM-C and FREEDOM-C2 Results

Complexities of Using Oral Treprostinil Role of Support Staff

Selexipag

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)